Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm Group™ Presents The ‘JCA Mauvernay Award 2013’

Published: Tuesday, October 08, 2013
Last Updated: Monday, October 07, 2013
Bookmark and Share
Doctors Kitabayashi and Yano will receive awards during the General Assembly of the 72nd Annual Conference of the JCA in Yokohama.

Debiopharm Group™ (Debiopharm) will be presenting the ‘JCA-Mauvernay Award’ on October 5, to Doctors Issay Kitabayashi from Tokyo National Cancer Center Research Institute for his basic research on ‘Molecular study of acute myeloid leukemia and its application for therapy’ and Seiji Yano from Kanazawa University for his applied research on ‘Circumvention of molecular targeted drug resistance in lung cancer’.

Doctors Kitabayashi and Yano will receive their Awards during the General Assembly of the 72nd Annual Conference of the Japanese Cancer Association (JCA) in Yokohama on the following theme: ‘Cancer research providing hope to fight against cancer’.

Dr. Tetsuo Noda, President of the JCA and a Debiopharm Group representative will present the trophies to both scientists.

“The selecting committee members chose the nominees for the high standard and application possibilities of their research. Debiopharm is honored to be part of this Award with the JCA and wishes both scientists success with their work,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Dr Kitabayashi focuses on the molecular study of the basis of the development of acute myeloid leukemia (AML). He shows that it is related to chromosomal rearrangements modifying the function of genes involved in transcription and hematopoiesis (AML1, PML, MOZ).

Molecular drugs like EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors (TKIs) show dramatic effects in lung cancer patients. However resistance to EGFR-TKIs is a major problem in current clinical practice.

Dr Yano aims to conduct clinical trials to elucidate and overcome the molecular mechanisms involved in the resistance to lung cancer drugs and to establish treatments to overcome it.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncotest and Debiopharm Announce a Successful Partnership
Successful completion of first biomarker projects at Oncotest.
Wednesday, April 24, 2013
Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor
Study to test Debio 0932 in patients with advanced non-small cell lung cancer.
Friday, August 17, 2012
Debiopharm and Vifor Pharma Sign an Exclusive Agreement
Distribution and commercialization of Pamorelin® LA in Switzerland.
Monday, May 21, 2012
Scientific News
Flowering Regulation Mechanism Discovered
Monash researchers have discovered a new mechanism that enables plants to regulate their flowering in response to raised temperatures.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Nanoparticles Present Sustainable Way to Grow Food Crops
Nanoparticle technology can help reduce the need for fertilizer, creating a more sustainable way to grow crops such as mung beans.
How Scientists Use DNA to Track Disease Outbreaks
They’re the top questions on everyone’s mind when a new disease outbreak happens: where did the virus come from? When did this happen? How long has it been spreading in a particular country or group of people?
Genetic Risk Factors of Disparate Diseases Share Similar Biological Underpinnings
Penn Institute for Biomedical Informatics and colleagues identify "roadmap" of disease mechanisms to identify candidate drug targets.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Stem Cells Know How to Unwind
Research led by the Babraham Institute with collaborators in the UK, Canada and Japan has revealed a new understanding of how an open genome structure supports the long-term and unrestricted developmental potential in embryonic stem cells.
HIV Particles Used to Trap Intact Mammalian Protein Complexes
Belgian scientists from VIB and UGent developed Virotrap, a viral particle sorting approach for purifying protein complexes under native conditions.
Childhood Asthma Research Receives $2M
Research into the impact of a child’s upbringing and social and physical environments on the development of asthma will receive $2 million to tackle the condition that affects as many as one in three Canadians.
Growing Stem Cells More Safely
Nurturing stem cells atop a bed of mouse cells works well, but is a non-starter for transplants to patients – Brown University scientists are developing a synthetic bed instead.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!